OC.10 Association between vasoactive-vasodilating therapy and reduced detection of pulmonary arterial hypertension in systemic sclerosis: evidence from a EUSTAR study
Nicola Farina(Vita-Salute San Raffaele University), Cosimo Bruni(University of Florence), V Smith(Ghent University Hospital), Luca Idolazzi(University of Verona), E Hachulla(Inserm), Oliver Distler(University Hospital of Zurich), Simona Truglia(Sapienza University of Rome), Emmanuel Chatelus(Laboratoire National de Référence), Anna Wojteczek(Gdańsk Medical University), Philipp Klemm(Kerckhoff Klinik), Madelon Vonk(Radboud University Nijmegen), Hilde Jenssen Bjørkekjær(Hospital of Southern Norway), Andra Balanescu(Carol Davila University of Medicine and Pharmacy), Jeska K de Vries-Bouwstra(Leiden University Medical Center), David Launay(Inserm), Serena Guiducci(University of Florence), Roberta Foti(Policlinico Universitario di Catania), Yannick Allanore(Université Paris Cité), Christina Bergmann(Universitätsklinikum Erlangen), Christopher P Denton(The Royal Free Hospital), Silvia Bellando-Randone(University of Florence), Anna Maria Hoffmann Vold(University of Florence), Marie-Elise Truchetet(Centre Hospitalier Universitaire de Bordeaux), Lorenzo Tofani(University of Florence), Marco Matucci-Cerinic(Vita-Salute San Raffaele University), Sébastien Sanges(Inserm)
Cited by 0
Related Papers
Mapping and predicting mortality from systemic sclerosis
|Annals of the Rheumatic Diseases|2017|699
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells
|Nature Medicine|2017|290
Autophagy regulates TNFα-mediated joint destruction in experimental arthritis
|Annals of the Rheumatic Diseases|2012|265